Apellis Pharmaceuticals (APLS) Stock Overview
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
APLS Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Apellis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.39 |
| 52 Week High | US$40.45 |
| 52 Week Low | US$16.10 |
| Beta | 0.29 |
| 1 Month Change | 95.12% |
| 3 Month Change | 60.79% |
| 1 Year Change | 75.61% |
| 3 Year Change | -47.76% |
| 5 Year Change | -1.25% |
| Change since IPO | 187.88% |
Recent News & Updates
Recent updates
Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing
Mar 31Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Jul 29
Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers
May 09
SYFOVRE And EMPAVELI Will Broaden Treatment Options Globally
SYFOVRE's strategic expansion and dominant GA market role could significantly drive revenue growth and international market penetration.The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26%
Apr 11Apellis Pharmaceuticals: A Mixed Bag
Mar 05Apellis: Saved By The October Data
Dec 25Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
Oct 01Apellis: Rare Kidney Disease Data Leads To Possible First To Market
Aug 09Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 14Shareholder Returns
| APLS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 127.9% | 2.3% | -0.3% |
| 1Y | 75.6% | 31.7% | 16.1% |
Return vs Industry: APLS exceeded the US Biotechs industry which returned 31.7% over the past year.
Return vs Market: APLS exceeded the US Market which returned 16% over the past year.
Price Volatility
| APLS volatility | |
|---|---|
| APLS Average Weekly Movement | 39.4% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: APLS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: APLS's weekly volatility has increased from 21% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 736 | Cedric Francois | apellis.com |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA.
Apellis Pharmaceuticals, Inc. Fundamentals Summary
| APLS fundamental statistics | |
|---|---|
| Market cap | US$5.14b |
| Earnings (TTM) | US$22.39m |
| Revenue (TTM) | US$1.00b |
Is APLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLS income statement (TTM) | |
|---|---|
| Revenue | US$1.00b |
| Cost of Revenue | US$398.09m |
| Gross Profit | US$605.69m |
| Other Expenses | US$583.30m |
| Earnings | US$22.39m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 60.34% |
| Net Profit Margin | 2.23% |
| Debt/Equity Ratio | 123.0% |
How did APLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 19:45 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apellis Pharmaceuticals, Inc. is covered by 34 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Colleen Kusy | Baird |
| Eliana Merle | Barclays |